PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-20.13%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-41.85%
Negative gross profit growth while CSIQ is at 247.66%. Joel Greenblatt would examine cost competitiveness or demand decline.
83.00%
EBIT growth above 1.5x CSIQ's 14.22%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
84.65%
Operating income growth above 1.5x CSIQ's 29.93%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
77.59%
Positive net income growth while CSIQ is negative. John Neff might see a big relative performance advantage.
77.72%
Positive EPS growth while CSIQ is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
77.72%
Positive diluted EPS growth while CSIQ is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.54%
Share reduction while CSIQ is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.54%
Reduced diluted shares while CSIQ is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
521.21%
OCF growth of 521.21% while CSIQ is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
2000.43%
FCF growth of 2000.43% while CSIQ is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
7082.42%
10Y revenue/share CAGR at 50-75% of CSIQ's 12272.23%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
409.62%
5Y revenue/share CAGR under 50% of CSIQ's 845.18%. Michael Burry would suspect a significant competitive gap or product weakness.
15.78%
3Y revenue/share CAGR under 50% of CSIQ's 455.48%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
5951.95%
OCF/share CAGR of 5951.95% while CSIQ is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
311.99%
5Y OCF/share CAGR above 1.5x CSIQ's 163.13%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
141.29%
3Y OCF/share CAGR under 50% of CSIQ's 1418.56%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-498.12%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-595.14%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-331.67%
Negative 3Y CAGR while CSIQ is 3.41%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
75.78%
5Y equity/share CAGR at 75-90% of CSIQ's 100.53%. Bill Ackman might push for an improved ROE or share repurchase strategy to keep up.
2.84%
Below 50% of CSIQ's 13.12%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-27.31%
Firm’s AR is declining while CSIQ shows 16.11%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
4.77%
We show growth while CSIQ is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
3.87%
Positive asset growth while CSIQ is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-5.96%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
0.76%
Debt shrinking faster vs. CSIQ's 1.59%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
-5.33%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
0.03%
SG&A declining or stable vs. CSIQ's 66.72%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.